Literature DB >> 12610728

The alternative use of exons 2 and 3 in cathepsin B mRNA controls enzyme trafficking and triggers nuclear fragmentation in human cells.

Kathrin Müntener1, Roman Zwicky, Gabor Csucs, Antonio Baici.   

Abstract

Pathological overexpression and trafficking of the cysteine peptidase cathepsin B depend in part on the composition of its mRNA. To investigate the roles of the alternatively spliced exons 2 and 3 in the 5'-untranslated region of cathepsin B mRNA we produced constructs of cathepsin B fused to green fluorescent protein. Expression and trafficking of the fluorescent chimeric products was followed in living human immortalized chondrocytes and HeLa cells. Although synthesized at different rates, proteins encoded by the full transcript and by that missing exon 2 followed a classic route, with the endosomal-lysosomal compartment as the final target. The point-mutated variant missing the glycosylation site for lysosomal targeting followed the secretory pathway. A truncated form of cathepsin B lacking the signal peptide and part of the propeptide, and encoded by the construct missing exons 2 and 3, was neither found in the Golgi apparatus nor in vesicles, but rather in the cytoplasm as patches associated with membranous and short fibrillar elements. This particular form of truncated cathepsin B produced nuclear damage and shrinking of the trans Golgi network and of the acidic compartment. The C-terminal, six-amino acid-long propeptide of cathepsin B did not exhibit a discernible role in protein trafficking.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12610728     DOI: 10.1007/s00418-002-0487-y

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  28 in total

1.  Observing proteases in living cells.

Authors:  K Moin; L Demchik; J Mai; J Duessing; C Peters; B F Sloane
Journal:  Adv Exp Med Biol       Date:  2000       Impact factor: 2.622

2.  In vivo expression of an alternatively spliced human tumor message that encodes a truncated form of cathepsin B. Subcellular distribution of the truncated enzyme in COS cells.

Authors:  S Mehtani; Q Gong; J Panella; S Subbiah; D M Peffley; A Frankfater
Journal:  J Biol Chem       Date:  1998-05-22       Impact factor: 5.157

3.  Microglial secreted cathepsin B induces neuronal apoptosis.

Authors:  P J Kingham; J M Pocock
Journal:  J Neurochem       Date:  2001-03       Impact factor: 5.372

4.  Maturation of human procathepsin B. Proenzyme activation and proteolytic processing of the precursor to the mature proteinase, in vitro, are primarily unimolecular processes.

Authors:  L Mach; J S Mort; J Glössl
Journal:  J Biol Chem       Date:  1994-04-29       Impact factor: 5.157

Review 5.  Molecular regulation, membrane association and secretion of tumor cathepsin B.

Authors:  B A Frosch; I Berquin; M R Emmert-Buck; K Moin; B F Sloane
Journal:  APMIS       Date:  1999-01       Impact factor: 3.205

6.  Cathepsin B expression and down-regulation by gene silencing and antisense DNA in human chondrocytes.

Authors:  Roman Zwicky; Kathrin Müntener; Mary B Goldring; Antonio Baici
Journal:  Biochem J       Date:  2002-10-01       Impact factor: 3.857

7.  Interleukin-1 beta-modulated gene expression in immortalized human chondrocytes.

Authors:  M B Goldring; J R Birkhead; L F Suen; R Yamin; S Mizuno; J Glowacki; J L Arbiser; J F Apperley
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

8.  Identification of two new exons and multiple transcription start points in the 5'-untranslated region of the human cathepsin-B-encoding gene.

Authors:  I M Berquin; L Cao; D Fong; B F Sloane
Journal:  Gene       Date:  1995-07-04       Impact factor: 3.688

9.  Nuclear localization of cystatin B, the cathepsin inhibitor implicated in myoclonus epilepsy (EPM1).

Authors:  M Riccio; R Di Giaimo; S Pianetti; P P Palmieri; M Melli; S Santi
Journal:  Exp Cell Res       Date:  2001-01-15       Impact factor: 3.905

10.  Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor.

Authors:  L Foghsgaard; D Wissing; D Mauch; U Lademann; L Bastholm; M Boes; F Elling; M Leist; M Jäättelä
Journal:  J Cell Biol       Date:  2001-05-28       Impact factor: 10.539

View more
  8 in total

Review 1.  Innovative techniques and applications in histochemistry and cell biology.

Authors:  Esther Asan
Journal:  Histochem Cell Biol       Date:  2003-11-28       Impact factor: 4.304

2.  Cathepsin B: Basis Sequence: Mouse.

Authors:  Dora Cavallo-Medved; Kamiar Moin; Bonnie Sloane
Journal:  AFCS Nat Mol Pages       Date:  2011-04-10

Review 3.  Cathepsin B: A sellsword of cancer progression.

Authors:  Olja Mijanović; Ana Branković; Alexander N Panin; Solomiia Savchuk; Peter Timashev; Ilya Ulasov; Maciej S Lesniak
Journal:  Cancer Lett       Date:  2019-02-20       Impact factor: 8.679

4.  A double-headed cathepsin B inhibitor devoid of warhead.

Authors:  Patricia Schenker; Pietro Alfarano; Peter Kolb; Amedeo Caflisch; Antonio Baici
Journal:  Protein Sci       Date:  2008-09-16       Impact factor: 6.725

5.  The C-terminal subunit of artificially truncated human cathepsin B mediates its nuclear targeting and contributes to cell viability.

Authors:  Felix Bestvater; Claudia Dallner; Eberhard Spiess
Journal:  BMC Cell Biol       Date:  2005-04-04       Impact factor: 4.241

6.  PDMS-PMOXA-Nanoparticles Featuring a Cathepsin B-Triggered Release Mechanism.

Authors:  Daniel Ehrsam; Fabiola Porta; Janine Hussner; Isabell Seibert; Henriette E Meyer Zu Schwabedissen
Journal:  Materials (Basel)       Date:  2019-09-03       Impact factor: 3.623

Review 7.  Extralysosomal cathepsin B in central nervous system: Mechanisms and therapeutic implications.

Authors:  Junjun Ni; Fei Lan; Yan Xu; Hiroshi Nakanishi; Xue Li
Journal:  Brain Pathol       Date:  2022-04-12       Impact factor: 7.611

8.  CTSB is a negative prognostic biomarker and therapeutic target associated with immune cells infiltration and immunosuppression in gliomas.

Authors:  Kaiming Ma; Xin Chen; Weihai Liu; Suhua Chen; Chenlong Yang; Jun Yang
Journal:  Sci Rep       Date:  2022-03-11       Impact factor: 4.996

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.